# Andrea Sartore‐Bianchi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrea-sartore-bianchi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,414 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 78 |
| i10-index | 184 |
| Last Known Institution | University of Milan |
| OpenAlex ID | https://openalex.org/A5030218831 |
| ORCID iD | https://orcid.org/0000-0003-0780-0409 |
| Works | 657 |

## Researcher papers

- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-multitargeted-pan-trk-ros1-and-alk/)
- [Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab](https://scholariq.org/papers/association-of-kras-p-g13d-mutation-with-outcome-in-patients-with-chemotherapy/)
- [Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study](https://scholariq.org/papers/fruquintinib-versus-placebo-in-patients-with-refractory-metastatic-colorectal/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [University of Milan](https://scholariq.org/institutions/university-of-milan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.